John Mumm is a serial biotechnology entrepreneur who, as a young researcher, demonstrated the importance of the cytokine, interleukin -10 (IL-10), in activating the immune system to destroy tumors. That research led to the use of Pegylated IL-10 to treat patients with pancreatic cancer and other solid tumors through his work at ARMO Biosciences, a company he founded and was later acquired by Eli Lilly in 2018.
Dr. Fussell represents a diverse array of clients in various intellectual property matters, including patent and trademark prosecution and litigation. She performs due diligence, freedom-to-operate, validity, and patentability analyses in the chemical and life sciences industries. She has a wide range of experience in the biotechnology, pharmaceutical, and chemical arts, including medical devices, biofuels, probiotics, plants, herbicides, fertilizers, seeds, nucleic acids, proteins, enzymes, carbohydrates, diagnostics, methods of treating cancer, cancer diagnostics, and agents for treating cancer. Dr. Fussell has negotiated and drafted a wide variety of agreements relating to intellectual property interests, including settlement agreements.
TEDCO’s Tammi Thomas Selected for Leadership Greater Washington 2022 Cohort. Established over 35 years ago, LGW has developed nearly 2,000 executive-level leaders from the District of Columbia, Virginia, and Suburban Maryland through its flagship offering, the Signature Program. It’s an intensive ten-month program that exposes professionals to regional civic issues through education, connection, and knowledge sharing. With the purpose to leverage collective knowledge and resources to make the Greater Washington region a more dynamic and collaborative community.
5 Questions with Eric A. Stahlberg, PhD, Director Bioinformatics and Data Science, Frederick National Laboratory for Cancer Research
Dr. Eric Stahlberg is director of Biomedical Informatics and Data Science at the Frederick National Laboratory for Cancer Research (FNL). Stahlberg has been instrumental in establishing FNL’s high-performance computing initiative and in assembling scientific teams across multiple, complex organizations to advance predictive oncology.
Adaptive Phage Therapeutics, Inc., a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has appointed Michele Wales, Ph.D., J.D., as Chief Legal Officer. Dr. Wales joins APT with extensive experience in litigation and intellectual property law, specifically within the life sciences industry.
Dr. Kayla Valdes is a Senior Manager at Horizon Therapeutics, a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare diseases. Prior to joining Horizon, Dr. Valdes worked at the National Institutes of Health as a Senior Program Manager on the Cure Sickle Cell Initiative. She was also the Associate Director of Scientific Programs at the Drug Information Association (DIA), where she developed DIA’s global content strategy by providing scientific expertise in therapeutic drug development and regulatory policy.
Ariel Gruswitz, JD, has joined Facility Logix as associate director. She will be responsible for
leading the firm’s consulting services practice and expanding its Feasibility and Market Analysis
Bill Snider is a Partner at BroadOak and leads the firm’s growth capital investing activities. Mr. Snider has more than 25 years of institutional investment experience.
Orgenesis Inc., a global biotech company working to unlock the full potential of cell and gene therapies, has appointed Luke Thorstenson as Director of Business Development. As Director of Business Development, his core responsibilities include setting the strategy for major Cell and Gene Therapy (CGT) initiatives and implementing the Orgenesis point-of-care platform in the United States. In addition, he will identify global opportunities for growth and analyze the development of value creation units and business units. He will also manage and establish new partnerships with research institutions like Johns Hopkins University, including the launch of several CGT specific facilities here in Baltimore
Dr. Hasan is a molecular microbiologist specialized in genomics, microbiome R&D, and strategic development of technology innovation in the biotech and life science industries. His work has resulted in multiple patents and hundreds of peer-reviewed articles, abstracts, and conference proceedings in the field of microbial genomics, microbiome, molecular ecology, and infectious diseases.